MTMin-Chien Tsai

Min-Chien Tsai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Min-Chien Tsai has a total of 65 co-authors. Here are the top co-authors by number of shared publications:

  • Chin-Sheng Lin

    Tri‐Service General Hospital, National Defense Medical University

    4 shared publications
  • Sy-Jou Chen

    Department of Emergency Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan

    4 shared publications
  • Chin-Sheng Lin

    Division of Cardiology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan; Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan

    3 shared publications
  • Shih-Hung Tsai

    Department of Emergency Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan

    3 shared publications
  • Shu Chien

    Department of Bioengineering and Medicine, Institute of Engineering in Medicine University of California San Diego La Jolla California USA

    2 shared publications
  • Yi-Ping Chuang

    Department and Graduate Institute of Microbiology and Immunology, National Defense Medical Center, Taipei, Taiwan

    2 shared publications

Latest Publications

  • Intracellular Galectin-3 as a Crucial Regulator of Foam Cell Formation and Apoptosis Progression Through the Modulation of Membrane Lipid Rafts

    by Wen-Cheng Liu, Chin-Sheng Lin, Chen-Ling Luo, Weng-Yu Yang, Cheng-Hung Yang, Mei-Ling Cheng, Min-Chien Tsai, Wei-Shiang Lin, Hao-Ai Shui, Yi-Ping Chuang


  • Melatonin Ameliorates Atherosclerotic Plaque Vulnerability by Regulating PPARδ‐Associated Smooth Muscle Cell Phenotypic Switching

    by Sy‐Jou Chen, Hung‐Che Chien, Shih‐Hung Tsai, Yu‐Sin Jheng, Yi Chen, Po‐Shiuan Hsieh, Pi‐Fen Tsui, Shu Chien, Min‐Chien Tsai

    Vulnerable atherosclerotic plaque rupture, the leading cause of fatal atherothrombotic events, is associated with an increased risk of mortality worldwide. Peroxisome proliferator–activated receptor delta (PPARδ) has been shown to modulate vascular smooth muscle cell (SMC) phenotypic switching, and, hence, atherosclerotic plaque stability. Melatonin reportedly plays a beneficial role in cardiovascular diseases; however, the mechanisms underlying improvements in atherosclerotic plaque vulnerability remain unknown. In this study, we assessed the role of melatonin in regulating SMC phenotypic switching and its consequential contribution to the amelioration of atherosclerotic plaque vulnerability and explored the mechanisms underlying this process. We analyzed features of atherosclerotic plaque vulnerability and markers of SMC phenotypic transition in high‐cholesterol diet (HCD)–fed apolipoprotein E knockout (ApoE−/−) mice and human aortic SMCs (HASMCs). Melatonin reduced atherosclerotic plaque size and necrotic core area while enhancing collagen content, fibrous cap thickness, and smooth muscle alpha‐actin positive cell coverage on the plaque cap, which are all known phenotypic characteristics of vulnerable plaques. In atherosclerotic lesions, melatonin significantly decreased the synthetic SMC phenotype and KLF4 expression and increased the expression of PPARδ, but not PPARα and PPARγ, in HCD‐fed ApoE−/− mice. These results were subsequently confirmed in the melatonin‐treated HASMCs. Further analysis using PPARδ silencing and immunoprecipitation assays revealed that PPARδ plays a role in the melatonin‐induced SMC phenotype switching from synthetic to contractile. Collectively, we provided the first evidence that melatonin mediates its protective effect against plaque destabilization by enhancing PPARδ‐mediated SMC phenotypic switching, thereby indicating the potential of melatonin in treating atherosclerosis.


  • Activation of heme oxygenase‐1 by laminar shear stress ameliorates high glucose‐induced endothelial cell and smooth muscle cell dysfunction

    by Hung‐Che Chien, Yu‐Lin Wang, Yun‐Chin Tu, Pi‐Fen Tsui, Min‐Chien Tsai

    High glucose (HG)‐induced endothelial cell (EC) and smooth muscle cell (SMC) dysfunction is critical in diabetes‐associated atherosclerosis. However, the roles of heme oxygenase‐1 (HO‐1), a stress‐response protein, in hemodynamic force‐generated shear stress and HG‐induced metabolic stress remain unclear. This investigation examined the cellular effects and mechanisms of HO‐1 under physiologically high shear stress (HSS) in HG‐treated ECs and adjacent SMCs. We found that exposure of human aortic ECs to HSS significantly increased HO‐1 expression; however, this upregulation appeared to be independent of adenosine monophosphate‐activated protein kinase, a regulator of HO‐1. Furthermore, HSS inhibited the expression of HG‐induced intercellular adhesion molecule‐1, vascular cell adhesion molecule‐1, and reactive oxygen species (ROS) production in ECs. In an EC/SMC co‐culture, compared with static conditions, subjecting ECs close to SMCs to HSS and HG significantly suppressed SMC proliferation while increasing the expression of physiological contractile phenotype markers, such as α‐smooth muscle actin and serum response factor. Moreover, HSS and HG decreased the expression of vimentin, an atherogenic synthetic phenotypic marker, in SMCs. Transfecting ECs with HO‐1‐specific small interfering (si)RNA reversed HSS inhibition on HG‐induced inflammation and ROS production in ECs. Similarly, reversed HSS inhibition on HG‐induced proliferation and synthetic phenotype formation were observed in co‐cultured SMCs. Our findings provide insights into the mechanisms underlying EC‐SMC interplay during HG‐induced metabolic stress. Strategies to promote HSS in the vessel wall, such as continuous exercise, or the development of HO‐1 analogs and mimics of the HSS effect, could provide an effective approach for preventing and treating diabetes‐related atherosclerotic vascular complications.


  • Peroxisome proliferator‐activated receptor δ improves the features of atherosclerotic plaque vulnerability by regulating smooth muscle cell phenotypic switching

    by Chih‐Feng Lien, Chin‐Sheng Lin, Song‐Kun Shyue, Po‐Shiuan Hsieh, Sy‐Jou Chen, Yi‐Tan Lin, Shu Chien, Min‐Chien Tsai

    Background and Purpose: Vascular smooth muscle cells (SMCs) undergo phenotypic switching during sustained inflammation, contributing to an unfavourable atherosclerotic plaque phenotype. PPARd plays an important role in regulating SMC functions; however, its role in atherosclerotic plaque vulnerability remains unclear. Here, we explored the pathological roles of PPARd in atherosclerotic plaque vulnerability in severe atherosclerosis and elucidated the underlying mechanisms.Experimental Approach: Plasma levels of PPARd were measured in patients with acute coronary syndrome (ACS) and stable angina (SA). SMC contractile and synthetic phenotypic markers, endoplasmic reticulum (ER) stress, and features of atherosclerotic plaque vulnerability were analysed for the brachiocephalic artery of apolipoprotein E-knockout (ApoE(-/-)) mice, fed a high-cholesterol diet (HCD) and treated with or without the PPARd agonist GW501516. In vitro, the role of PPARd was elucidated using human aortic SMCs (HASMCs).Key Results: Patients with ACS had significantly lower plasma PPARd levels than those with SA. GW501516 reduced atherosclerotic plaque vulnerability, a synthetic SMC phenotype, ER stress markers, and NLRP3 inflammasome expression in HCD-fed ApoE(-/-) mice. ER stress suppressed PPARd expression in HASMCs. PPARd activation inhibited ER stress-induced synthetic phenotype development, ER stress-NLRP3 inflammasome axis activation and matrix metalloproteinase 2 (MMP2) expression in HASMCs. PPARd inhibited NF?B signalling and alleviated ER stress-induced SMC phenotypic switching.Conclusions and Implications: Low plasma PPARd levels may be associated with atherosclerotic plaque vulnerability. Our findings provide new insights into the mechanisms underlying the protective effect of PPARd on SMC phenotypic switching and improvement the features of atherosclerotic plaque vulnerability.


  • Open Access

    An Artificial Intelligence-Based Alarm Strategy Facilitates Management of Acute Myocardial Infarction

    by Wen-Cheng Liu, Chin Lin, Chin-Sheng Lin, Min-Chien Tsai, Sy-Jou Chen, Shih-Hung Tsai, Wei-Shiang Lin, Chia-Cheng Lee, Tien-Ping Tsao, Cheng-Chung Cheng

    (1) Background: While an artificial intelligence (AI)-based, cardiologist-level, deep-learning model for detecting acute myocardial infarction (AMI), based on a 12-lead electrocardiogram (ECG), has been established to have extraordinary capabilities, its real-world performance and clinical applications are currently unknown. (2) Methods and Results: To set up an artificial intelligence-based alarm strategy (AI-S) for detecting AMI, we assembled a strategy development cohort including 25,002 visits from August 2019 to April 2020 and a prospective validation cohort including 14,296 visits from May to August 2020 at an emergency department. The components of AI-S consisted of chest pain symptoms, a 12-lead ECG, and high-sensitivity troponin I. The primary endpoint was to assess the performance of AI-S in the prospective validation cohort by evaluating F-measure, precision, and recall. The secondary endpoint was to evaluate the impact on door-to-balloon (DtoB) time before and after AI-S implementation in STEMI patients treated with primary percutaneous coronary intervention (PPCI). Patients with STEMI were alerted precisely by AI-S (F-measure = 0.932, precision of 93.2%, recall of 93.2%). Strikingly, in comparison with pre-AI-S (N = 57) and post-AI-S (N = 32) implantation in STEMI protocol, the median ECG-to-cardiac catheterization laboratory activation (EtoCCLA) time was significantly reduced from 6.0 (IQR, 5.0–8.0 min) to 4.0 min (IQR, 3.0–5.0 min) (p < 0.01). The median DtoB time was shortened from 69 (IQR, 61.0–82.0 min) to 61 min (IQR, 56.8–73.2 min) (p = 0.037). (3) Conclusions: AI-S offers front-line physicians a timely and reliable diagnostic decision-support system, thereby significantly reducing EtoCCLA and DtoB time, and facilitating the PPCI process. Nevertheless, large-scale, multi-institute, prospective, or randomized control studies are necessary to further confirm its real-world performance.


  • Open Access

    Potential Role of Protein Kinase C in the Pathophysiology of Diabetes-Associated Atherosclerosis

    by Chih-Feng Lien, Sy-Jou Chen, Min-Chien Tsai, Chin-Sheng Lin

    Diabetes mellitus is a metabolic syndrome that affects millions of people worldwide. Recent studies have demonstrated that protein kinase C (PKC) activation plays an important role in hyperglycemia-induced atherosclerosis. PKC activation is involved in several cellular responses such as the expression of various growth factors, activation of signaling pathways, and enhancement of oxidative stress in hyperglycemia. However, the role of PKC activation in pro-atherogenic and anti-atherogenic mechanisms remains controversial, especially under hyperglycemic condition. In this review, we discuss the role of different PKC isoforms in lipid regulation, oxidative stress, inflammatory response, and apoptosis. These intracellular events are linked to the pathogenesis of atherosclerosis in diabetes. PKC deletion or treatment with PKC inhibitors has been studied in the regulation of atherosclerotic plaque formation and evolution. Furthermore, some preclinical and clinical studies have indicated that PKCβ and PKCδ are potential targets for the treatment of diabetic vascular complications. The current review summarizes these multiple signaling pathways and cellular responses regulated by PKC activation and the potential therapeutic targets of PKC in diabetic complications.


  • Open Access

    Epigallocatechin-3-gallate exhibits immunomodulatory effects in human primary T cells

    by Shih-Chung Huang, Yung-Hsi Kao, Shao-Fu Shih, Min-Chien Tsai, Chin-Sheng Lin, Liv Weichien Chen, Yi-Ping Chuang, Pi-Fen Tsui, Ling-Jun Ho, Jenn-Haung Lai, et al.


  • Laminar shear stress upregulates the expression of PPARs in vascular endothelial cells under high free fatty acid‑induced stress

    by Yu-Lin Wang, Chen-Te Chen, Che-Se Tung, Min-Chien Tsai

    Shear stress has been reported to result in various metabolic effects in endothelial cells (ECs), which in turn contribute to the regulation of their vascular functions. Peroxisome proliferator‑activated receptors (PPARs) have been reported to regulate lipid metabolism and have been implicated in metabolic disorders. The present study assessed the effects of laminar shear stress on the expression of PPARs in ECs in the presence of high concentrations of free fatty acids (FFAs). Human aortic ECs (HAECs) were treated with a high concentrations of palmitic acid (PA) and exposed to high shear stress (HSS) or low shear stress (LSS). Western blotting and ELISA were performed to quantify protein expression and assess prostacyclin production. The results revealed that long‑term application of HSS to PA‑treated HAECs induced PPAR‑α, ‑δ and -γ protein expression. Additionally, LSS induced higher levels of PPAR‑α protein expression in PA‑treated HAECs compared with those after HSS. HAECs exposed to HSS also released prostacyclin (PGI2). However, HAECs treated with high concentrations of PA also produced high levels of PGI2 in the perfusion media in response to HSS compared with the static PA group. HSS also reduced the static PA‑induced expression of intercellular adhesion molecule‑1 and monocyte chemoattractant protein‑1. The results demonstrated that HAECs increases the expression of all three peroxisome proliferator‑activated receptor isoforms in response to shear metabolic stress at high FFA concentrations. The present study may provide preliminary insights into the potential roles of PPARs as an effective treatment method against metabolic disturbances that can result in EC dysfunction.


  • Open Access

    Carvedilol Ameliorates Experimental Atherosclerosis by Regulating Cholesterol Efflux and Exosome Functions

    by Sy-Jou Chen, Pi-Fen Tsui, Yi-Ping Chuang, Dapi Meng-Lin Chiang, Liv Weichien Chen, Shu-Ting Liu, Feng-Yen Lin, Shih-Ming Huang, Shih-Hua Lin, Wan-Lin Wu, et al.

    Carvedilol (Cav), a nonselective β-blocker with α1 adrenoceptor blocking effect, has been used as a standard therapy for coronary artery disease. This study investigated the effects of Cav on exosome expression and function, ATP-binding cassette transporter A1 (ABCA1) expression, and cholesterol efflux that are relevant to the process of atherosclerosis. Human monocytic (THP-1) cell line and human hepatic (Huh-7) cells were treated with Cav, and cholesterol efflux was measured. Exosomes from cell culture medium or mice serum were isolated using glycan-coated recognition beads. Low-density lipoprotein receptor knockout (ldlr−/−) mice were fed with high-fat diet and treated with Cav. Cav accentuated cholesterol efflux and enhanced the expressions of ABCA1 protein and mRNA in both THP-1 and Huh-7 cells. In addition, Cav increased expression and function of exosomal ABCA1 in THP-1 macrophage exosomes. The mechanisms were associated with inhibition of nuclear factor-κB (NF-κB) and protein kinase B (Akt). In hypercholesterolemic ldlr−/− mice, Cav enhanced serum exosomal ABCA1 expression and suppressed atherosclerosis by inhibiting lipid deposition and macrophage accumulation. Cav halts atherosclerosis by enhancing cholesterol efflux and increasing ABCA1 expression in macrophages and in exosomes, possibly through NF-κB and Akt signaling, which provides mechanistic insights regarding the beneficial effects of Cav on atherosclerotic cardiovascular disease.